Patients carrying the CYP3A4*4 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.